Sodium Compound Of Arsenic Patents (Class 424/624)
  • Publication number: 20140348947
    Abstract: This document discloses molecules having the following formula (“Formula I”):
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: Tony K. Trullinger, Ricky Hunter, Negar Garizi, Maurice C. H. Yap, Ann M. Buysse, Dan Pernich, Timothy C. Johnson, Kristy Bryan, Carl DeAmicis, Yu Zhang, Noormohamed M. Niyaz, CaSandra Lee McLeod, Ronald Ross, JR., Yuanming Zhu, Peter Lee Johnson, Joseph D. Eckelbarger, Marshall H. Parker
  • Patent number: 8784797
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: July 22, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Brirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Publication number: 20120195974
    Abstract: The invention disclosed in this document concerns controlling mealybugs.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Mayank Yadav, Suresh Ramachandran, Sanjoy Kundu
  • Publication number: 20120121724
    Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.
    Type: Application
    Filed: January 20, 2012
    Publication date: May 17, 2012
    Inventor: Todd Maibach
  • Publication number: 20110091574
    Abstract: Methods of treating adenocarcinoma cells such as NSCLC cells are disclosed that depend upon the level of functionally active LKB1 expressed in the cancer cells being treated. In one embodiment, the cancer cells express functionally active LKB1 and the method comprises contacting those cells with a LKB1-stimulating amount of a COX-2-specific inhibitor in combination with an inhibiting amount of a specific inhibitor of mTOR. In another embodiment, the cancer cells express about 25 percent or less of the normal, functional LKB1 expressed by non-transformed cells of the same type are contacted with a growth inhibiting amount of an agent that inhibits cellular metabolism and induces energetic stress.
    Type: Application
    Filed: February 13, 2009
    Publication date: April 21, 2011
    Applicant: Catholic Healthcare West
    Inventors: Landon J. Inge, Keith D. Coon
  • Publication number: 20090011047
    Abstract: The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid metal salt is sodium meta-arsenita (AsO2Na) or potassium meta-arsenite (AsO2K). The effective amount of arsenous acid alkaline or earth alkaline metal salt is 0.0001-1500 mg/kg, preferably 1-1000 mg/kg, more preferably 1-150 mg/kg, and most preferably 50-100 mg/kg of body weight/day. The administration form of the pharmaceutical compositions of the invention is preferably oral, such as a tablet, capsule, powder and/or solution with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: May 9, 2006
    Publication date: January 8, 2009
    Inventor: Bernardus Rademaker
  • Publication number: 20080279961
    Abstract: It is demonstrated in the present invention that G-quadruplex ligands can be used to both shorten telomeres and inhibit telomerase by causing telomere uncapping. The invention relates to compositions and methods of treating cancer stem cells comprising the administration of G-quadruplex ligands, such as 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4), which can effectively inhibit or reduce the growth of cancer stem cells. The invention also relates to a synergistic effect in inhibiting or reducing the growth cancer stem cells when a G-quadruplex ligand is combined with a mitotic spindle poison, such as paclitaxel, or other agents used in the treatment of cancer and disease. The invention also relates to RHPS4 inducing non-cancerous cell and non-cancerous stem cell proliferation.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 13, 2008
    Inventor: Angelika M. BURGER
  • Publication number: 20080193560
    Abstract: The present invention relates to the use of arsenic compounds such as sodium meta arsenite (NaAsO2), arsenic trioxide (As2O3), and arsenic hexoxide (As4O6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
    Type: Application
    Filed: January 31, 2008
    Publication date: August 14, 2008
    Inventors: Michael Hwang, Yong Yin Yang
  • Patent number: 7217413
    Abstract: The invention concerns the use of novel agents including cell death, and in particular, an agent for overexpression of the PML protein on nuclear bodies, combined with interferons, to induce the death of undesirable cells and simulate an immune reaction.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: May 15, 2007
    Assignees: Institut de la Sante et de la Recherde Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Marcel Koken, Frédérique Quignon, Hugues De The, Jean-Claude Ameisen, Frédéric De Bels
  • Patent number: 7208519
    Abstract: The invention includes a pesticidal compound comprising at least one organic phenolic compound and at least one salt comprising a divalent cation. Preferably, the organic phenolic compound is chosen from Carvacrol, thymol or combinations thereof; and is derived from a natural source, preferably extracted from a member of the family Labiatae or Verbenacea. Preferably the divalent cation is a transition metal salt and more preferably is zinc chloride or zinc sulfate. The invention also includes methods of eradicating, repelling or preventing infestations of pests, including such pests as insects, mites, ova, fungus, or parasites. The methods comprise the steps of preparing a pesticidal compound, combining it with a carrier, and applying it to the affected area.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: April 24, 2007
    Assignee: Van Beek Natural Science, LLC
    Inventor: Dusan Ninkov
  • Patent number: 6861075
    Abstract: A storage-stable biocidal aerated gel composition comprises from 30 to 97% by weight of water, from 0.2 to 5% by weight of a gelling agent selected from xanthan gum, sodium alginate and neutralised carboxyvinyl polymer from 2 to 5% by weight of a fine particulate, hydrophobic silicone-treated silica having a surface area of from 80 to 300 m2/g and from 0.004 to 20% by weight of a biocide which said composition is in the form of fine particles of an aqueous gel containing the water, gelling agent and the biocide, the surfaces of which fine particles are coated with a coating of the finely particulate hydrophobic silica. The biocidal aerated gel composition can be used to control pests using one or more appropriate biocides in the composition.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: March 1, 2005
    Assignee: Sorex Limited
    Inventor: Roland S. Twydell
  • Patent number: 6844369
    Abstract: The invention includes a pesticidal compound comprising at least one organic phenolic compound and at least one salt comprising a divalent cation. Preferably, the organic phenolic compound is chosen from Carvacrol, thymol or combinations thereof; and is derived from a natural source, preferably extracted from a member of the family Labiatae or Verbenacea. Preferably the divalent cation is a transition metal salt and more preferably is zinc chloride or zinc sulfate. The invention also includes methods of eradicating, repelling or preventing infestations of pests, including such pests as insects, mites, ova, fungus, or parasites. The methods comprise the steps of preparing a pesticidal compound, combining it with a carrier, and applying it to the affected area.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: January 18, 2005
    Assignee: Van Beek Global, LLC
    Inventor: Dusan Ninkov
  • Patent number: 5709890
    Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: January 20, 1998
    Assignee: Donlar Corporation
    Inventor: J. Larry Sanders